Jump to content
  • Announcements

    • Bodine van Wingerden


      Per 23-3-2018 the ISBT Forum is temporarily closed. We are in the process of setting up a new forum within the MyISBT section of the ISBT website. We are happy to welcome you back on the new ISBT Forum soon. Please check your email for an update once the new Forum is available. Thank you for your understanding.

      Best wishes Team ISBT

Bodine van Wingerden

  • Content count

  • Joined

  • Last visited


About Bodine van Wingerden

  • Rank
    Advanced Member
  1. Going to Toronto?

    Dear Young Investigators, Are you thinking about going to the Toronto Congress this year? In June ISBT will once again organise an International Congress on blood transfusion and transfusion medicine. The deadline for submitting your abstract is February 22, just over one month away. The main requirements for submitting your abstracts are that it should be on a topic related to transfusion medicine, you should be under 35 years of age (40 if you are applying for the Harold Gunson Fellowship, more information also in this post), and the first, submitting, and presenting author of your abstract. Find out more on the Toronto website! When you submit your abstract you can also apply for the Harold Gunson Fellowship, a travel grant that will cover your travel, hotel and registration costs. If you want to know more about applying for the Harold Gunson Fellowship you can find more information about submitting your abstract on the congress website. In Toronto another Young Investigators Breakfast will be organised where you can network with professionals in your field. Some of you have attended the breakfast meeting at past ISBT congresses, feel free to share your experience so fellow young researchers know what they can gain from this meeting. At the 34th International Congress in 2016, ISBT introduced the Young Investigator Session. In this scientific session we gave Young Investigators the opportunity to present their transfusion medicine research in an oral presentation. If you would like to apply for this session you can tick the 'Young Investigator'-box when you submit your abstract for the congress. Note; the deadline for submitting your abstract is February 22, 2018. Look around this forum for tips on writing your abstract and presenting it. How often have you submitted an abstract to a transfusion medicine congress?
  2. A few thoughts on academic writing

    Hi Gloria, Thank you for sharing your thoughts and your experience from the workshop! If you look at the ISBT abstract submission guidelines (http://isbtweb.org/fileadmin/user_upload/ISBT_Toronto_Abstract_Guidelines.pdf) you will see the requirements set by ISBT for submitted abstracts to our congresses. Reviewers look at the proper structure of the abstract, the presence of data, and the use of correct, understandable English. Please note, it is not required to use very sophisticated language at all! Actually, papers are expected to be written in such a correct, understandable manner that even people who are not experts in that field are able to understand the research. If you feel you need more help before you submit your abstract to an ISBT congress, we do offer help with reviewing your abstract (see the abstract submission guidelines, under HELP OR REVIEW OF THE STRUCTURE AND LANGUAGE OF YOUR ABSTRACT). Good luck!
  3. Live Journal Club

    Please join ISBT on September 26 at 15:00 CET when Drs. Yazer and Seheult will discuss the WOMAN study (Lancet 2017;389:2105-2116), a randomized trial of tranexamic acid in post partum hemorrhage. This discussion will be held in the style of a journal club, and there will be the opportunity for the audience to engage with the speakers about the paper at the end of the session. Members of ISBT will receive a registration link via email.
  4. A few thoughts on academic writing

    Hi Soumya, Did you happen to go to the Workshop on writing a scientific paper in Copenhagen? I heard it was very well received! I don't know if anyone can share their experience? And I am sure you will overcome it!
  5. Titles and qualifications

    Some responses given by our followers on LinkedIn: Taiwo Ukashah Oloko 1.Medical Laboratory Scientist 2.Medical Laboratory Scientist Yamama Tamim Hello, in yhe province of Québec in Canada, you should have succeeded the college diploma in "Technolgies d'analyses biomédicales" and be a member of the "Ordre professionnel des technologistes médicaux du Québec". The title would than be"medical laboratory technologist". Need any more info, send me a Linkedin message pls. Oladapo Asiyanbi 1.Medical Laboratory Scientist 2. Medical Laboratory Technicians 3. Pathologists 4. Fellow Postgraduate West Africa College in Laboratory Medicine (FWACP.Lab) 4. Fellow Postgraduate National College in Laboratory Medicine (FNCP. Lab) 5. Fellow Postgraduate West Africa College in Heamatology (FWAP.H) 6. Fellow Postgraduate National College in Heamatology (FNMC.H) Marie Kobayashi, CG, MB(ASCP) You could also be a CLS (Clinical Laboratory Scientist). Dr Munira Borhany Medical laboratory technician Medical laboratory Scientists Post graduate Fellowship in Haematology and Blood Bank. Pathologists Dr'Soumya Das In India... It is Medical laboratory technologists.... Gopal Sharma if a person is passed 10+2 with science he can do DMLT and he is able to do cross match blood for patients under supervision of pathologist, but if he is BACHELOR of medical lab. technology he become medical lab. technologist and as per drug and cosmetic act 1940 he is able to do unsupervised blood grouping, antibody screening and cross matching.but final signature by blood bank medical officer. Deepak Kumar I think blood bank technical supervisor has to right to report signing . MSC Biochemist has signing right in biochemistry report . ISBT should think up gradation of technician and technical supevisor.
  6. Blood Transfusion Reference Books

    Hi Abiy! I think your question is one that could interest a lot of others here on the forum! But maybe it would be good to give some specifications on which topics related to transfusion medicine you are most interested in? There is so much out there, are you looking for best practices on blood storage for example, or how to find and retain donors? Or are you more interested in the latest blood tests? Thanks! Have a good weekend, Bodine
  7. Questions from Webinar 2

    If you did not attend the second ISBT Webinar presented by Masja de Haas, you can find the transcribed questions that were asked during the webinar below. On the ISBT Academy ePortal a recording of the webinar is now available as well. If you have any further questions or comments feel free to post them below. Question 1: Eugene Zhiburt All blood transfusion in Russia are K-matched. K-positive RBCs are not issued from blood centers. Rate of K-positive donors is 6 %. Answer: That indeed is very interesting. As I understand this comment, then K-positive red blood cells are never issued from blood centres, so they are also not issued to male recipients if I am correct. So then you are excluding 6% of your blood donors or perhaps you are using their donation for other purposes. And, well that is something that you can think of, of course. In the Netherlands it is around 9%. So it is something to think about, because then you have to explain 9% of the donors why you are using their gift in a certain way. I think with the policy to protect a selected population (the women in their fertile years) then you already have a lot of benefits so. But I think it is very interesting that in Russia they have chosen this way. Comment of Eugene: They can donate plasma and platelets. Question 2: Leo van de Watering How often do you find a discrepancy in foetal blood group between the different prenatal tests, and how do you deal with this? Answer: Between the different prenatal tests, we are doing the foetal RhD-typing only once, in week 27 of the pregnancy. Sometimes we need to repeat it, but only if we have questions about the test results. I don’t often see many changes. We also do foetal typing early in the pregnancy, and that is for the women with an alloimmunized pregnancy. And in those cases, we are using foetal genetic markers to confirm that foetal DNA is present. And in those cases, we sometimes see, that it is very difficult to judge whether there is sufficient amount of foetal DNA present to do a reliable typing, and then we ask for another sample. In those cases sometimes we are typing around week 12, and indeed we have difficulties to judge whether the child is positive, and then later on in the pregnancy we see a very clear positive test result. But the timings we use now to do the foetal RhD-typing, we don’t see many problems in having a reliable foetal RhD test result. Question 3 Mali Polonca What is the c- and -E- transfusion policy for women under 45 years? Answer: (Because of poor audio conditions in the recording Masja has summarized her answer here) In the NL we observed a reduction in the prevalence of anti-c and anti-E among women aged under 45 years. This will reduce the number of pregnancies in which laboratory investigations and clinical monitoring needs to be done. However, anti-c and anti-E less often cause severe haemolytic disease of the fetus and newborn. Therefore, it will take a very long time before we can see a positive impact of a cE-matched transfusion policy in for women in their reproductive age on the number of pregnancies with severe haemolytic disease of the foetus and newborn. Question 4: Ji Yanli Could you give more information about the effect of anti-K on erytropoiesis? Did anti-K result in abortion or anaemia during the early age of pregnancy? Answer: Thank you for this question Ji Yanli. Indeed, the Anti-K can result in very early anaemia, and if you have to do an intrauterine transfusion before week 4 of pregnancy, that increases the risks on adverse effects. And it increases the risk that something is going wrong. That is something that we have experienced in The Netherlands during the last fifteen years. Currently, we are investigating whether you can postpone that first intrauterine transfusion by treating pregnant women with intravenous immunoglobulin. That should already start very early on in the pregnancy. And you are hoping that you are lowering the transfer of the anti-K from the mother to the child – or that you are doing something else which is reducing the haemolysis or anaemia in the very young foetus. So it really can result in already an abortion or fatality, before week 20 of the pregnancy. Question 5: Leo van de Watering After pregnancy microchimerism may develop. Can remaining cells from earlier pregnancies interfere with the blood typing? Answer: Indeed, I see many cases with microchimerism, after pregnancy. But when we are isolating the plasma, we are implementing some centrifugation steps to reduce the number of cells that can give residual DNA in the blood samples. Although it can give some background signal (the DNA from those cells, or foetuses or children from previous pregnancies), in the algorithm that we are using, it does not have such a big influence on the test-results but there can be many false positivities because of that reason.
  8. Transfusion Today

    Hi Linley, Thank you for your message and thank you for your contribution to Transfusion Today! This article will then most likely be included in the September Issue of TT. I will send you an email with the deadline for sending in the final article. Best wishes, Bodine van Wingerden Team ISBT
  9. Join the I TRY IT 2.0 programme!

    The ISBT TTID working party is offering the next phase of the programme I TRY IT 2.0. The programme will focus on the steps from research data to publication. This programme is open for all Young Investigators who have already collected research data and want further training in data analysis and writing of scientific manuscripts. The format is online lectures, homework, and an in-person session at the ISBT Congress in Copenhagen. Participants will gain further experience of peer review on their own work, and also facilitate peer review, and feedback of abstracts and manuscripts prepared by other participants. For more information please view the 'At a glance'-document attached to this post. If you are interested in I TRY IT 2.0 complete the application form and send it by email with the subject heading I TRY IT 2.0 to Jessica Bailey via JBailey2@Bloodsystems.org. At a glance TTID WP YI T 2.0 2017 Version E (Automatisch opgeslagen).pdf ISBT WP TTID I try it 2.0 Application form.docx
  10. Yesterday ISBT posted this article on Facebook. It was published in Vox Sanguinis on February 20th, 2017 and identified 14 randomized trials that enrolled 26 374 participants. The researchers conducted a review and meta-analysis that excluded the benefit from transfusion of fresher red blood cells. http://onlinelibrary.wiley.com/doi/10.1111/vox.12495/abstract What do you think of this surprising outcome?
  11. Hi Victor,

    Happy birthday from all of us here at ISBT Central Office!

    Best wishes,

    Bodine van Wingerden
    Team ISBT

  12. A few thoughts on academic writing

    I really relate to the struggles with actually starting to write (not so much with watching grass grow ). I was wondering how you go about this, do you first like to read as much previous research as you can find and then start writing, or first read a couple of similar articles, write a little, more reading and write as you go along? I have tried both approaches but found it difficult to maintain a structured overview of all the data and previous findings when I first read a lot of material rather than take in small bits at a time.. I was wondering how others go about this? Do you use a special method?